DOVER, Del. & OXFORD, England– Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the ethical clinical AI company, today announces that it has signed a Strategic Research Agreement (SRA) and a Collaboration Agreement with Sentara Healthcare (“Sentara”), a leading healthcare system serving patients in Virginia and northeastern North Carolina through 12 acute hospitals with more than 300 sites of care.
Sentara will join 11 UK NHS Trusts and U.S. Health Systems who are partners and shareholders in Sensyne Health. The new agreement is Sensyne’s third U.S. partnership since launching in the U.S. in December 2020. The addition of Sentara’s 3.6 million patients brings Sensyne’s combined total of de-identified patient data for medical research to 21.7 million patients.
The partnership combines both life sciences research and healthcare algorithm development that will deliver value back to Sentara and its patients. The agreement will enable the ethical application of clinical AI research by Sensyne through analyzing Sentara’s patient dataset to improve patient care and accelerate medical research. As part of a collaboration agreement, Sentara also becomes the first of several U.S. health systems that will partner with Sensyne to implement new clinical algorithms to support patients with CKD and CHF.
Jordan Asher, Executive Vice President and Chief Physician Executive of Sentara Healthcare, said:
“The combination of data and clinical expertise has the power to drive innovation, further advance research and enhance our ability to deliver complex and high-specialized clinical care to the communities we serve. The Sensyne partnership has the potential to help our organization continue our mission of improving health every day in critical areas of healthcare, including health equity.”
